PAION AG · ISIN: DE000A0B65S3 · EQS - adhoc news

PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults

PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults Aachen (Germany), 03 April 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Commission (EC) has approved remimazolam for the induction and maintenance of general anesthesia in adults in the EU (including the countries of the European Economic Area, EEA). In addition,...

XFRA:PA8 Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News PAION AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (5)
Directors Dealings (1)
Short Selling (DE) (1)
Short Selling (UK) (0)
03 April 2023 01:20PM
PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults
DE000A0B65S3
PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults Aachen (Germany), 03 April 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Commission (EC) has approved remimazolam f...
PAION AG
About the publication
03 April 2023 01:20PM
PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults
DE000A0B65S3
PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults Aachen (Germany), 03 April 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Commission (EC) has approved remimazolam f...
PAION AG
About the publication
31 March 2023 07:15PM
PAION AG implements resolved capital reduction
DE000A0B65S3
PAION AG implements resolved capital reduction   Aachen (Germany), 31 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensive care announces that the resolutions of the Extraordin...
PAION AG
About the publication
31 March 2023 07:15PM
PAION AG implements resolved capital reduction
DE000A0B65S3
PAION AG implements resolved capital reduction   Aachen (Germany), 31 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensive care announces that the resolutions of the Extraordin...
PAION AG
About the publication
30 March 2023 07:30AM
PAION AG reports on fiscal year 2022
DE000A0B65S3
 PAION AG reports on fiscal year 2022 Combined revenues of EUR 33.2 million Cash and cash equivalents of EUR 10.6 million as of 31 December 2022 Positive EBITDA of EUR 1.5 million Capital reduction carried out in the first quarter of 2023 Initiatives to expand commercial distribution continued, including the successful expansion of partner ne...
PAION AG
About the publication
30 March 2023 07:30AM
PAION AG reports on fiscal year 2022
DE000A0B65S3
 PAION AG reports on fiscal year 2022 Combined revenues of EUR 33.2 million Cash and cash equivalents of EUR 10.6 million as of 31 December 2022 Positive EBITDA of EUR 1.5 million Capital reduction carried out in the first quarter of 2023 Initiatives to expand commercial distribution continued, including the successful expansion of partner ne...
PAION AG
About the publication
16 March 2023 10:00AM
PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS
DE000A0B65S3
PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS   Sponsored Symposium & poster presentation about angiotensin II at 42nd ISICEM 2023, 21-24 March 2023, Brussels PAION to present new data from a post hoc analysis of the ATHOS-3 study with angiotensin II   Aachen (Germany), 16 March 2023 – PAION AG (ISIN DE000A0B65...
PAION AG
About the publication
16 March 2023 10:00AM
PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS
DE000A0B65S3
PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS   Sponsored Symposium & poster presentation about angiotensin II at 42nd ISICEM 2023, 21-24 March 2023, Brussels PAION to present new data from a post hoc analysis of the ATHOS-3 study with angiotensin II   Aachen (Germany), 16 March 2023 – PAION AG (ISIN DE000A0B65...
PAION AG
About the publication
27 January 2023 12:59PM
PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults
DE000A0B65S3
PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults Aachen (Germany), 27 January 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Medicines Agency’s Committ...
PAION AG
About the publication
25 January 2023 05:35PM
Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing
DE000A0B65S3
PAION AG: Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing Aachen (Germany), 25 January 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesi...
PAION AG
About the publication
19 January 2023 10:30AM
​​​​​​​PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL
DE000A0B65S3
PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL  Aachen (Germany), 19 January 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensiv...
PAION AG
About the publication
16 December 2022 10:19AM
PAION AG issues statement on planned capital measure
DE000A0B65S3
PAION AG issues statement on planned capital measure Aachen (Germany), 16 December 2022 - PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anaesthesia and intensive care, announced on Wednesday, 14 December 2022,...
PAION AG
About the publication
16 December 2022 10:19AM
PAION AG issues statement on planned capital measure
DE000A0B65S3
PAION AG issues statement on planned capital measure Aachen (Germany), 16 December 2022 - PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anaesthesia and intensive care, announced on Wednesday, 14 December 2022,...
PAION AG
About the publication
14 December 2022 01:41PM
PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares
DE000A0B65S3
Public disclosure of inside information pursuant to Article 17 of the Regulation (EU) No 596/2014 (Market Abuse Regulation) PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of sharesAachen, December 14, 2022 – The Management Board of specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3;...
PAION AG
About the publication
14 December 2022 01:41PM
PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares
DE000A0B65S3
Public disclosure of inside information pursuant to Article 17 of the Regulation (EU) No 596/2014 (Market Abuse Regulation) PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of sharesAachen, December 14, 2022 – The Management Board of specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3;...
PAION AG
About the publication
30 November 2022 05:28PM
PAION AG announces change in Management Board
DE000A0B65S3
PAION AG announces change in Management Board Chairman of the Executive Board Dr. James Phillips leaves the company effective 30 November 2022 Current Supervisory Board member Gregor Siebert will be appointed as a member and new Chairman of the Management Board until 30 November 2023 Aachen (Germany), 30 November 2022 - PAION AG (ISIN DE000A0B65S...
PAION AG
About the publication
30 November 2022 05:28PM
PAION AG announces change in Management Board
DE000A0B65S3
PAION AG announces change in Management Board Chairman of the Executive Board Dr. James Phillips leaves the company effective 30 November 2022 Current Supervisory Board member Gregor Siebert will be appointed as a member and new Chairman of the Management Board until 30 November 2023 Aachen (Germany), 30 November 2022 - PAION AG (ISIN DE000A0B65S...
PAION AG
About the publication
30 November 2022 05:21PM
CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
DE000A0B65S3
Ad-hoc announcement pursuant to Art. 17 of the EU Market Abuse Regulation (MAR)   PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023 Aachen (Germany), 30 November 2022 – PAION AG (ISIN: DE000A0B65S3 / WKN A0B65S) announces...
PAION AG
About the publication
30 November 2022 05:21PM
PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
DE000A0B65S3
Ad-hoc announcement pursuant to Art. 17 of the EU Market Abuse Regulation (MAR)   PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023 Aachen (Germany), 30 November 2022 – PAION AG (ISIN: DE000A0B65S3 / WKN A0B65S) announces...
PAION AG
About the publication
16 November 2022 11:40AM
PAION AG enters partnership with Viatris and expands sales activities in Europe
DE000A0B65S3
PAION AG enters partnership with Viatris and expands sales activities in Europe Viatris, leveraging its Global Healthcare Gateway in partnership with Paion shall distribute the products Remimazolam, Eravacycline and Angiotensin II in a total of 7 European target markets Focus remains on expansion of commercial sales in Europe  Aachen, Germany, 1...
PAION AG
About the publication
16 November 2022 11:40AM
PAION AG enters partnership with Viatris and expands sales activities in Europe
DE000A0B65S3
PAION AG enters partnership with Viatris and expands sales activities in Europe Viatris, leveraging its Global Healthcare Gateway in partnership with Paion shall distribute the products Remimazolam, Eravacycline and Angiotensin II in a total of 7 European target markets Focus remains on expansion of commercial sales in Europe  Aachen, Germany, 1...
PAION AG
About the publication
16 November 2022 07:30AM
PAION AG reports financial results for the first nine months of 2022
DE000A0B65S3
PAION AG reports financial results for the first nine months of 2022 Combined revenues of EUR 25.6 million Cash and cash equivalents of EUR 10.4 million as of 30 September 2022 PAION raises guidance for 2022 and expects EBITDA in the corridor of EUR -1.5 million to EUR +0.5 million Transformation into commercial specialty pharma company progres...
PAION AG
About the publication
16 November 2022 07:30AM
PAION AG reports financial results for the first nine months of 2022
DE000A0B65S3
PAION AG reports financial results for the first nine months of 2022 Combined revenues of EUR 25.6 million Cash and cash equivalents of EUR 10.4 million as of 30 September 2022 PAION raises guidance for 2022 and expects EBITDA in the corridor of EUR -1.5 million to EUR +0.5 million Transformation into commercial specialty pharma company progres...
PAION AG
About the publication
15 November 2022 04:28PM
PAION AG raises EBITDA forecast for fiscal year 2022
DE000A0B65S3
Ad-hoc announcement pursuant to Art. 17 of the EU Market Abuse Regulation (MAR)PAION AG raises EBITDA forecast for fiscal year 2022 Aachen (Germany), 15 November 2022 – PAION AG (ISIN: DE000A0B65S3 / WKN A0B65S) announces that, based on the results for the first nine months of 2022, it is raising the outlook for the full year 2022 published with t...
PAION AG
About the publication
15 November 2022 04:28PM
PAION AG raises EBITDA forecast for fiscal year 2022
DE000A0B65S3
Ad-hoc announcement pursuant to Art. 17 of the EU Market Abuse Regulation (MAR)PAION AG raises EBITDA forecast for fiscal year 2022 Aachen (Germany), 15 November 2022 – PAION AG (ISIN: DE000A0B65S3 / WKN A0B65S) announces that, based on the results for the first nine months of 2022, it is raising the outlook for the full year 2022 published with t...
PAION AG
About the publication
14 November 2022 03:10PM
PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
DE000A0B65S3
PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN TTY Biopharm is planning to launch this new sedative in December 2022 Approximately 1.3 million invasive medical procedures take place annually in Taiwan, of which ~50-80% use moderate sedation PAION already has selected partnerships to lice...
PAION AG
About the publication
14 November 2022 03:10PM
PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
DE000A0B65S3
PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN TTY Biopharm is planning to launch this new sedative in December 2022 Approximately 1.3 million invasive medical procedures take place annually in Taiwan, of which ~50-80% use moderate sedation PAION already has selected partnerships to lice...
PAION AG
About the publication
31 August 2022 01:34PM
PAION AG reports financial results for the first half-year 2022
DE000A0B65S3
PAION AG reports financial results for the first half-year 2022 Transformation into commercial specialty pharma company continues Financial position strengthened to support commercial activities in Europe by sale of Chinese remimazolam patents and future royalties to Humanwell for EUR 20.5 million Expansion of partner networks through licensing...
PAION AG
About the publication
31 August 2022 01:34PM
PAION AG reports financial results for the first half-year 2022
DE000A0B65S3
PAION AG reports financial results for the first half-year 2022 Transformation into commercial specialty pharma company continues Financial position strengthened to support commercial activities in Europe by sale of Chinese remimazolam patents and future royalties to Humanwell for EUR 20.5 million Expansion of partner networks through licensing...
PAION AG
About the publication
01 August 2022 10:00AM
PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY
DE000A0B65S3
PAION Launches eravacycline for the treatment of complicated intra-abdominal infections in Adults in Germany   Eravacycline has the status as a reserve antibiotic Providing broad-spectrum coverage against bacterial pathogens   Aachen (Germany), 01 August 2022 – The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchan...
PAION AG
About the publication
01 August 2022 10:00AM
PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY
DE000A0B65S3
PAION Launches eravacycline for the treatment of complicated intra-abdominal infections in Adults in Germany   Eravacycline has the status as a reserve antibiotic Providing broad-spectrum coverage against bacterial pathogens   Aachen (Germany), 01 August 2022 – The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchan...
PAION AG
About the publication
24 June 2022 09:06AM
​​​​​​​PAION REPORTS SOLID PROGRESS WITH COMMERCIAL ACTIVITIES IN EUROPE
DE000A0B65S3
PAION REPORTS SOLID PROGRESS WITH COMMERCIAL ACTIVITIES IN EUROPE - Product rollouts in UK, Netherlands and Scandinavia going well, including formulary acceptance - Positive customer feedback following initial experience with PAION products Aachen (Germany), 24 June 2022 – The specialty pharma company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock...
PAION AG
About the publication
25 May 2022 03:00PM
​​​​​​​PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS MICHAEL SCHLENK AND GREGOR SIEBERT TO THE SUPERVISORY BOARD
DE000A0B65S3
PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS MICHAEL SCHLENK AND GREGOR SIEBERT TO THE SUPERVISORY BOARD - Agenda items approved with a large majority - Michael Schlenk and Gregor Siebert elected as successors to Dr Dr Antonijevic and Dr Jörg Spiekerkötter; Dr Hans Christoph Tanner re-elected Aachen (Germany), 25 May 202...
PAION AG
About the publication
18 May 2022 07:30AM
​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2022
DE000A0B65S3
PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2022   - Transformation into commercial specialty pharma company continues - Financial position strengthened to support commercial activities in Europe by sale of Chinese remimazolam patents and future royalties to Humanwell for EUR 20.5 million - Expansion of partner networ...
PAION AG
About the publication
27 April 2022 04:33PM
PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA
DE000A0B65S3
PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA - EUR 3.5 million upfront payment to PAION - 20% royalties on net sales Aachen (Germany), 27 April 2022 - PAION AG, a specialty pharma company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), and Cristália Produtos ...
PAION AG
About the publication
30 March 2022 10:00AM
PAION AG ANNOUNCES CHANGE IN MANAGEMENT BOARD
DE000A0B65S3
PAION AG ANNOUNCES CHANGE IN MANAGEMENT BOARD - Sebastian Werner to succeed Abdelghani Omari as Chief Financial Officer - New CFO of PAION AG with many years of experience at international pharmaceutical companies Aachen (Germany), 30 March 2022 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime ...
PAION AG
About the publication
30 March 2022 07:30AM
​​​​​​​PAION AG REPORTS ON FISCAL YEAR 2021
DE000A0B65S3
PAION AG REPORTS ON FISCAL YEAR 2021   - Transformation into commercial specialty pharma company following expansion of European product portfolio; own commercialisation of remimazolam, angiotensin II and eravacycline started in second half of 2021 - Remimazolam launched by partners in U.S. and South Korea - Financial position strengthened to ...
PAION AG
About the publication
27 January 2022 03:00PM
PAION AG ANNOUNCES CHANGE IN SUPERVISORY BOARD
DE000A0B65S3
PAION AG ANNOUNCES CHANGE IN SUPERVISORY BOARD Michael Schlenk to succeed Dr. Dr. Irina Antonijevic and to become candidate for the chairmanship of the Supervisory Board Aachen (Germany), 27 January 2022 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that the Sup...
PAION AG
About the publication
07 January 2022 01:59PM
​​​​​​​PAION ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED FUTURE ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP
DE000A0B65S3
PAION ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED FUTURE ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP Aachen (Germany), 07 January 2022 - Today, PAION AG, a specialty pharma company (FSE:PA8), and Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, a wholly-owned subsidiary of Humanwell Health...
PAION AG
About the publication
31 December 2021 12:38PM
PAION SUBMITS EXTENSION APPLICATION OF MARKETING AUTHORIZATION FOR REMIMAZOLAM IN THE INDICATION GENERAL ANESTHESIA TO THE EUROPEAN MEDICINES AGENCY
DE000A0B65S3
PAION SUBMITS EXTENSION APPLICATION OF MARKETING AUTHORIZATION FOR REMIMAZOLAM IN THE INDICATION GENERAL ANESTHESIA TO THE EUROPEAN MEDICINES AGENCY Aachen (Germany), 31 December 2021 - The Specialty Pharma Company PAION AG (FSE: PA8) today announces that PAION has submitted an extension application to the Marketing Authorization for remimazolam ...
PAION AG
About the publication
10 November 2021 07:30AM
​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2021
DE000A0B65S3
PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2021 - Transformation into commercial specialty pharma company following expansion of European product portfolio; angiotensin II (GIAPREZA(R)) and eravacycline (XERAVA(R)) successfully launched in Q3 2021 - PAION launches remimazolam (Byfavo(R)) in the UK and the Netherland...
PAION AG
About the publication
16 September 2021 02:00PM
PAION AG ANNOUNCES INITIATION OF PIVOTAL STUDY OF REMIMAZOLAM (BYFAVO(R)) IN PEDIATRIC PROCEDURAL SEDATION
DE000A0B65S3
PAION AG ANNOUNCES INITIATION OF PIVOTAL STUDY OF REMIMAZOLAM (BYFAVO(R)) IN PEDIATRIC PROCEDURAL SEDATION Aachen (Germany), 16 September 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) announces together with Acacia Pharma (Acacia), remimazolam licensee for the U.S., the initiation of...
PAION AG
About the publication
02 September 2021 02:00PM
PAION SIGNS EXCLUSIVE UK SUPPLY AND DISTRIBUTION AGREEMENT WITH CLINIGEN
DE000A0B65S3
PAION SIGNS EXCLUSIVE UK SUPPLY AND DISTRIBUTION AGREEMENT WITH CLINIGEN Aachen (Germany), 02 September 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that PAION has signed an exclusive partnership agreement with Clinigen for the supply and distribution of its products ...
PAION AG
About the publication
01 September 2021 10:00AM
PAION LAUNCHES XERAVA(R) (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN THE NETHERLANDS
DE000A0B65S3
PAION LAUNCHES XERAVA(R) (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN THE NETHERLANDS - Providing broad-spectrum coverage against bacterial pathogens - XERAVA(R) is the third product launched by PAION in Europe Aachen (Germany), 01 September 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A...
PAION AG
About the publication
31 August 2021 09:32AM
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO (REMIMAZOLAM) IN PROCEDURAL SEDATION IN SOUTH KOREA
DE000A0B65S3
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO (REMIMAZOLAM) IN PROCEDURAL SEDATION IN SOUTH KOREA - Fully-fledged entry into the endoscopy market by adding an indication for 'induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less' - Use expanded to various surgeries, with 'Byfavo 50m...
PAION AG
About the publication
23 August 2021 07:30AM
PAION AG REPORTS FINANCIAL RESULTS FOR THE FIRST HALF-YEAR 2021
DE000A0B65S3
PAION AG REPORTS FINANCIAL RESULTS FOR THE FIRST HALF-YEAR 2021 - Remimazolam partner activities: Market launches in the U.S. and South Korea, total product sales of licensees of EUR 2.7 million. - EU market approval for remimazolam (Byfavo(R)) in procedural sedation; approval and product launch of Byfavo(R) in UK - Expansion of European produc...
PAION AG
About the publication
16 August 2021 11:00AM
PAION LAUNCHES BYFAVO(R) (REMIMAZOLAM) IN THE UK FOR PROCEDURAL SEDATION
DE000A0B65S3
PAION LAUNCHES BYFAVO(R) (REMIMAZOLAM) IN THE UK FOR PROCEDURAL SEDATION - Millions of procedures take place in the UK annually such as colonoscopies and bronchoscopies that require the use of procedural sedation - Byfavo(R) is the first product developed by PAION approved and launched in Europe Aachen (Germany), 16 August 2021 - The Specialty ...
PAION AG
About the publication
16 July 2021 11:09AM
PAION LAUNCHES GIAPREZA(R) (ANGIOTENSIN II) FOR THE TREATMENT OF REFRACTORY HYPOTENSION IN ADULTS WITH SEPTIC OR OTHER DISTRIBUTIVE SHOCK IN GERMANY
DE000A0B65S3
PAION LAUNCHES GIAPREZA(R) (ANGIOTENSIN II) FOR THE TREATMENT OF REFRACTORY HYPOTENSION IN ADULTS WITH SEPTIC OR OTHER DISTRIBUTIVE SHOCK IN GERMANY - GIAPREZA(R) is the first product launched by PAION in Europe Aachen (Germany), 16 July 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard)...
PAION AG
About the publication
More PAION AG related information
Type Total Last Made by Go to
Corporate Research 5 18th September 2023 EQS Group AG Corporate Research
Directors Dealings 1 28th December 2022 Siebert, Gregor DD
Short Seller (DE) 1 11th July 2014 Susquehanna International Group Limited SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN